NeuroSense Therapeutics Gets Nasdaq Minimum Bid Price Notice
Ticker: NRSNW · Form: 6-K · Filed: Aug 30, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-compliance, notification, stock-price
TL;DR
Nasdaq says NeuroSense's stock price is too low, they have time to fix it or get booted.
AI Summary
NeuroSense Therapeutics Ltd. announced on August 30, 2024, that it received a notification from Nasdaq regarding its minimum bid price. The company must regain compliance with the $1.00 minimum bid price requirement within a specified period to avoid delisting.
Why It Matters
Failure to meet Nasdaq's minimum bid price requirement could lead to the delisting of NeuroSense Therapeutics' shares, impacting investor confidence and liquidity.
Risk Assessment
Risk Level: medium — The company faces a potential delisting from Nasdaq if it cannot meet the minimum bid price requirement, which poses a significant risk to its stock.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — The company filing the report and receiving the notification.
- Nasdaq (company) — The stock exchange that issued the minimum bid price notification.
- August 30, 2024 (date) — The date NeuroSense Therapeutics announced the receipt of the Nasdaq notification.
FAQ
What is the specific requirement NeuroSense Therapeutics failed to meet according to Nasdaq?
NeuroSense Therapeutics received a notification from Nasdaq regarding its failure to meet the minimum bid price requirement of $1.00 per share.
What is the deadline for NeuroSense Therapeutics to regain compliance with Nasdaq's minimum bid price rule?
The filing states that the company must regain compliance within a specified period, though the exact end date is not detailed in this excerpt.
What are the potential consequences if NeuroSense Therapeutics does not regain compliance?
If NeuroSense Therapeutics does not regain compliance, its securities may be subject to delisting from the Nasdaq Capital Market.
What action did NeuroSense Therapeutics take upon receiving the notification?
NeuroSense Therapeutics issued a press release on August 30, 2024, announcing the receipt of the Nasdaq minimum bid price notification.
Where is NeuroSense Therapeutics Ltd. based?
NeuroSense Therapeutics Ltd. is based in Herzliya, Israel, with its principal executive offices located at 11 HaMenofim Street, Building B.
Filing Stats: 255 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-08-30 17:00:06
Filing Documents
- ea0212798-6k_neuro.htm (6-K) — 12KB
- ea021279801ex99-1_neuro.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 8KB
- 0001213900-24-074611.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: August 30, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3